You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

38 Results
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Apr 2025
Drug
Other Name(s): Aromasin®
Aug 2025
Drug
Other Name(s): Afinitor®
Jun 2019
Drug
Other Name(s): Xtandi®
Aug 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Jun 2019
Regimen
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
May 2019
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    exemestane
Aug 2025
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019

Pages